A Novel Approach to Assessing the Drug Susceptibility and Replication of Human Immunodeficiency Virus Type 1 Isolates
Author(s) -
Robert M. Jellinger,
Robert W. Shafer,
T. C. Merigan
Publication year - 1997
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/175.3.561
Subject(s) - zidovudine , didanosine , nevirapine , virology , lamivudine , biology , virus , reverse transcriptase , drug , antiviral drug , viral disease , polymerase chain reaction , viral load , pharmacology , genetics , gene , hepatitis b virus , antiretroviral therapy
Human immunodeficiency virus type 1 (HIV-1) drug susceptibility testing is often curtailed because such testing is expensive and time consuming. A colorimetric tetrazolium dye method previously used for high-throughput antiviral drug screening was adapted to assess the susceptibility of 16 HIV-1 isolates to zidovudine, didanosine, lamivudine, and nevirapine in MT-2 cells. Cell viability was assessed colorimetrically, and all measurements and calculations were automated. Each HIV-1 isolate was tested in > or = 5 assays to determine the reproducibility of the assay in HIV-1 isolates with known reverse-transcriptase mutations. The drug susceptibility of several mutant HIV-1 strains whose drug susceptibilities had not previously been well defined was also determined. Data on HIV-1 replication from the susceptibility assays indicated that some mutant HIV-1 isolates may have been less cytopathic in MT-2 cells than wild type HIV-1 isolates.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom